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ABSTRACT: The release of the opioid antagonist naltrexone from neutral poly(N-isopropylacrylamide) (PNIPAAM) microgels and negatively
charged PNIPAAM microgels containing acrylic acid groups (PNIPAAM-co-PAA) has been studied at various microgel and drug concen-
trations. The release curves were found to be well represented by the Weibull equation. The release rates were observed to be dependent
on the microgel concentration. At most conditions, the release from the charged microgels was slower than for the neutral microgels. In
addition, the charged microgels exhibited a release lag time, which was dependent on the microgel concentration. No significant lag time
could be observed for the neutral microgels. Increasing the naltrexone concentration did not significantly affect the release rates from
the neutral microgels, but the release from the charged microgels became faster. The microgels did not exhibit any significant cytotoxic
effect on HeLa cells at the tested concentrations. C© 2013 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci
103:227–234, 2014
Keywords: controlled release; drug delivery systems; macromolecular drug delivery; microencapsulation; microparticles; polymeric drug
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INTRODUCTION
Naltrexone (Fig. 1) is an opioid antagonist, and has been
used to treat heroin and alcohol addiction. However, oral
naltrexone formulations have drawbacks such as patient
noncompliance,1 fluctuating plasma levels,2 and the exten-
sive first-pass metabolism of naltrexone.3 Injectable de-
pot formulations that can give a sustained release of nal-
trexone over an extended period of time could prevent
the problems encountered with oral dosage forms. Sev-
eral systems such as poly(L-lactide) microspheres,4,5 poly
lactide-co-glycolide (PLGA) microspheres,6 poly(D,L-lactide-
co-glycolide) microspheres,7 polyethylene glycol-graft-methyl
methacrylate crosslinked nanoparticles,8 and nanoparti-
cles produced from a blend of poly(N-isopropylacrylamide-
acrylamide-vinylpyrrolidone) and PLGA9 have been suggested
for sustained release dosage forms for naltrexone. There is how-
ever still need for improving the release profile and drug loading
capacity of the systems. Utilizing new kinds of thermosensitive
in situ gelling microgels might therefore be of interest.
The release of a drug that is encapsulated into micro- or
nanoparticles is dependent on a number of factors such as
particle size,10–13 drug size,14,15 the degree of swelling of the
particles,16–18 erosion of the particles,19 and associative inter-
actions between the drug and the particles, for example, hy-
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drophobic interactions,15 hydrogen bonds,20,21 or electrostatic
interactions.14
Nano- and microparticles that are formed using thermosen-
sitive polymers with a lower critical solution temperature
(LCST) have a swollen structure at temperatures below the
transition temperature and a more compact (collapsed) struc-
ture at higher temperatures. This effect can be utilized both
to increase the loading capacity and modulate the release of
a drug from the particles. Increased loading rate and capac-
ity may be expected for drug loading in the swollen state,
whereas the drug release is often found to be slower when
the systems are heated to temperatures above the LCST of
the particles due to reduced porosity. This phenomenon has
been observed for several different systems such as: core–shell
nanoparticles containing a poly(L-lactic acid) core and a poly(N-
isopropylacrylamide) (PNIPAAM) thermosensitive shell,22
alginate-hydroxypropylcellulose microbeads,23 poly(N-vinyl
caprolactam) nanoparticles,24 poly(N-isopropylacrylamide-co-
caprolactam) microspheres,25 and PNIPAAM microspheres
grafted with poly(itaconic acid) groups.14 Interestingly, micro-
spheres of elastin-like polypeptides (ELP) exhibited faster re-
lease rates above the LCST due to the opening of micropores in
the microspheres by the contraction of the thermosensitive ELP
molecules.26 Faster release rates above the LCST was also ob-
served for chitosan-g-poly(N-vinylcaprolactam) and chitosan-g-
PNIPAAM nanoparticles.20,21 This was explained by the ability
of the drug to form hydrogen bonds with the nanoparticles at
temperatures below the LCST. This capacity was lost above the
LCST, and hence faster release rates are promoted.
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Figure 1. Chemical structure of naltrexone, PNIPAAM, and PAA.
For poly(N-isopropylacrylamide-co-acrylamide) and poly(N-
isopropylacrylamide-co-N-hydroxymethyl acrylamide) micro-
spheres, it was found that even though the drug release is
slower above the LCST, there is an enhanced release of drug
for a short period when the temperature is increased from be-
low to above the LCST.15,27 This effect was thought to be due
to drug molecules that are dissolved in the solvent inside the
swollen microspheres. When the samples are heated up, these
drug molecules are squeezed out together with the solvent dur-
ing the collapse of the network. Similar effects have also been
observed for other thermoresponsive systems.28
In this study, we have investigated PNIPAAM microgels as
a sustained drug delivery vehicle for naltrexone. The microgel
concentrations utilized in this study are quite high, and it is not
possible to measure their sizes using light scattering methods
due to multiple scattering. However, previous studies of the
same microgels at lower concentrations show that the microgels
are swollen and have an open structure at low temperatures.29
As the temperature is increased the microgels shrink, and at
temperatures above the LCST of PNIPAAM (ca. 32◦C) large
aggregates with a compact structure are formed.
The drug is loaded into the microgels at a low temperature.
At these conditions, the microgels are swollen in the solvent,
and this open structure should make it easier for the drug to
diffuse into the microgels. The microgel suspensions have a
low viscosity and can be easily administrated to the patient
through injection. When the samples are heated up to body
temperature, the microgels collapse and they also aggregate
into larger structures.29 A schematic illustration of a possible
mechanism for loading of naltrexone into the PNIPAAM mi-
crogels is depicted in Figure 2. The conjecture is that both the
more compact structure and the formation of larger aggregates
at 37◦C should slow down the diffusion of naltrexone out of
the microgels. As naltrexone contains hydrophobic domains,
associative interactions between the drug and the PNIPAAM
microgels could also result in slower drug release rates.
Naltrexone is positively charged at physiological pH.30 We
have therefore also studied PNIPAAM microgels containing
1 mol % acrylic acid groups to see if the electrostatic inter-
actions between the drug and the oppositely charged microgels
can slow down the release rates. At low microgel concentra-
tions, this low charge density was observed to have little effect
on the contraction and aggregation behavior of the microgels
in water.29 Any changes in the observed release profiles are
therefore mainly expected to be due to electrostatic interac-
tions between the drug and the microgels.
As for any proposed drug delivery system, the toxicity of
the formulation is of vital importance. We have therefore also
conducted in vitro cytotoxicity studies on the microgels at the
considered concentrations.
MATERIALS AND METHODS
The naltrexone (USPH1453504) was purchased from VWR In-
ternational (West Chester, Pennsylvania, USA), and the chem-
icals used for making the buffer solution were purchased from
Sigma–Aldrich (St. Louis, Missouri, USA).
Figure 2. Schematic illustration of the proposed loading of naltrexone into the microgels.
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Preparation of PNIPAAM Microgels
Negatively charged PNIPAAM microgels (MG-04) containing
1 mol % acrylic acid groups (PNIPAAM-co-PAA) and neu-
tral PNIPAAM microgels (without acrylic acid groups; MG-06)
were synthesized as described previously.29 The structures of
PNIPAAM and PAA are shown in Figure 1.
Sample Preparation
A PBS was used for the preparation of the samples for the dis-
solution tests. The buffer contained 16.8 mM Na2HPO4, 1.4 mM
KH2PO4, 137 mM NaCl, and 3.1 mM sodium azide. The pH of
the buffer was adjusted with acetic acid to 7.4.
For the release experiments, the microgels were dispersed in
PBS at the desired concentrations (0–4 wt %), and stirred for at
least 24 h. Afterward, the samples were placed in the fridge (ca.
4◦C) for at least another 24 h to ensure homogeneous suspen-
sions. Naltrexone (0.02–0.08 wt %) was loaded into the micro-
gels by dissolving it directly in the microgel suspensions. The
samples were then stirred for at least 24 h, and then placed in
the fridge for at least 48 h before the release experiments were
commenced. The concentrations given for naltrexone and the
microgel suspensions are of the prepared suspensions before
the samples were diluted down by the initiation of the release
experiments.
In Vitro Cytotoxicity Assay of the Microgels
HeLa cells (human epithelial cervical carcinoma cell line) were
maintained in culture at 37◦C, under 5% CO2, in Dulbecco’s
modified Eagle’s medium–high glucose (DMEM–HG; Sigma),
supplemented with 10% (v/v) heat inactivated fetal bovine
serum (Sigma), penicillin (100 U/mL), and streptomycin (100
:g/mL). HeLa cells grown in monolayer were detached by treat-
ment with 0.25% trypsin solution (Sigma).
The cell viability in the presence of the microgels was inves-
tigated by the modified Alamar Blue assay. This method, which
has been extensively used to assess the viability and/or prolifer-
ation of mammalian cells, employs a redox indicator whose color
(and fluorescence) changes in response to cell metabolic activity,
the blue nonfluorescent oxidized form (resazurin) originating
a pink and fluorescent molecule (resorufin) upon reduction.31
Briefly, HeLa cells were seeded at a cell density of 50,000
cells/well in 48-well plates and incubated at 37◦C for 24 h.
The microgels were suspended in Opti-MEM (reduced serum)
medium at different concentrations and were added to the cells.
The plates were left to incubate at 37◦C for 48 h. The medium
was replaced with 300 :L of 10% (v/v) Alamar Blue (Sigma)
dye in DMEM cell culture medium and the plates were fur-
ther incubated for 45 min at 37◦C. An aliquot of the super-
natant (150 :L) was collected from each well and transferred
to 96-well plates. The absorbance at 570 nm (A570) and 600 nm
(A600) (information provided by the supplier) was measured in
a SPECTRAmax PLUS 384 spectrophotometer. Cell viability
was calculated according to the equation:
Cell viability (%) = (A570 − A600) of treated cells
(A570 − A600) of control cells × 100 (1)
Release Experiments
The release experiments were conducted utilizing a SOTAX
USP Apparatus four flow through cell dissolution apparatus at
37◦C. 2.5 mL of the samples was placed in the flow-through cells
(which were filled with 1 mm glass beads to avoid turbulence
and ensure a laminar flow of the buffer through the cells32 and
left to equilibrate at 37◦C for 10 min before the release exper-
iments were initiated. During the release studies, 22.5 mL of
PBS (giving a total volume of 25 mL) was continuously pumped
through the flow through cells at a flow rate of 4 mL/min. The
microgels were prevented from escaping the cells by a combina-
tion of two filters: a membrane of regenerated cellulose with a
1 kDa cutoff (Z-MEM-AQU-425N from Postnova) followed by a
dialysis membrane (Spectra/Por 6 with a cutoff of 8000 Da). The
buffer was circulating in a closed system, and the circuit was
connected to a spectrophotometer (Pharmacia LKB – Ultrospec
III), which detected the released naltrexone by measuring the
absorbance at a wavelength of 282 nm every 2nd min for a total
release time of 5 h.
The threshold concentration for departure from sink condi-
tions for naltrexone is approximately 0.5 wt %,33 and accord-
ingly all release experiments have been conducted well within
sink conditions.
Evaluation of the Release Rates
The release data have been fitted to the Weibull equation34,35:
Mt
M∞
= 1 − exp
[
−
(
t − t0
τ d
)β]
(2)
where Mt is the amount of drug released at the time t, M∞ is
the maximum amount of drug released at infinite time, t0 is
the dissolution lag time, the rate constant τ d is the time after t0
when 63.2% of the drug has been released, and β is the shape
parameter of the release curve.
For the neutral microgels, t0 was always found to be zero
within the experimental errors. The release curves for these
microgels were therefore fitted using t0 ≡ 0 to reduce the num-
ber of fitting parameters.
The release curves for the samples where no lag time was ob-
served were also fitted to an equation where an extra term was
added to Eq. (2) to accommodate for a possible burst release
effect. However, this resulted in very poor fits, and the burst
release doses were always found to be zero within the experi-
mental errors. This indicates that the systems do not exhibit
any burst release, and the extra term were therefore not used
in the analyses of the data.
The Weibull equation is often found to give a good fit to ex-
perimental drug release data over the whole experimental time
scale.36–40 In spite of its statistical origin, the Weibull model
can be used to gain information about the physiochemical as-
pects behind the release profile. Both experimental data10–13
and Monte Carlo simulations41,42 show that the drug is released
slower from larger particles, that is, τ d becomes higher as the
particle size is increased. The reduction of the specific leak sur-
face (surface area/volume) of the particles with increasing size
plays an important role in this phenomenon.41,42
The shape parameter, β, may be related to the release
mechanism.36,43 Monte Carlo simulations also suggests that the
value of β depends both on the size of the particles (β decreases
when the particles becomes larger), on the shape of the parti-
cles, and on the ability of the drug molecules to move inside the
particle matrix.42 For Fickian diffusion, an increase of β should
indicate less disorder inside the particles.36
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RESULTS AND DISCUSSION
In Vitro Cytotoxicity
Because the microgels are intended for drug delivery purposes,
it is important that they do not exhibit any significant cytotoxic
effect. It has previously been found that PNIPAAM nanopar-
ticles did not exhibit any cytotoxicity at concentrations up to
about 1 wt %, whereas NIPAAM monomers were found to be
toxic even at low concentrations.44 We have tested the two mi-
crogels used in this study on HeLa cells using the same microgel
concentrations as for the release experiments. The cell viability
for different concentrations of the two microgels is displayed in
Figure 3. Comparing the viability of cells incubated with the
microgels to that of control cells, taken as 100%, it is noticeable
that microgels did not exhibit any significant cytotoxicity even
at relatively high concentrations. At the lower concentrations
assayed, the neutral PNIPAAM microgels apparently induced
an increase of cell viability relative to control cells. To correctly
interpret the meaning of this effect, it is necessary to take into
account the principle that underlies the technique used to as-
sess cell viability. The Alamar Blue assay uses a dye as an
oxidation–reduction indicator, whose reduction occurs inside
the cells31 and involves reductases and the mitochondrial elec-
tron chain.45 Therefore, compounds that promote an increase
of nonviable cells, which have no metabolic capacity, will in-
duce lower reduction of the dye. On the contrary, agents or
conditions that enhance cell metabolic activity and/or promote
higher rates of cell growth will induce higher levels of dye re-
duction. Both these phenomena (improvement of cell metabolic
activity and increase of cell proliferation) can be on the basis of
the high values of cell viability (>100%) found at low concen-
trations of neutral PNIPAAM microgels. This effect has been
observed before for other systems, and was attributed to the
surface properties of the systems.46 It is also possible that the
microgels act as a scaffold, thereby increasing the proliferation
rates of the cells.47
Figure 3. Effects of microgels on the viability of HeLa cells with
increasing concentrations at 37◦C. Values of cell viability, measured
by the Alamar Blue assay as described in Materials and Methods,
are expressed as a percentage of the untreated cells (control) and are
means±standard deviation obtained from triplicates in at least three
independent experiments.
In Vitro Release
The release profiles of 0.02 wt % naltrexone from suspensions
of the two microgels in phosphate buffer (pH 7.4) at 37◦C are
depicted in Figure 4. When a buffer solution containing naltrex-
one in the absence of any microgel suspension (0 wt % microgel)
is used, the time it takes for the system to detect 100% of the
naltrexone is very short (ca. 5 min). This indicates that the de-
tection delay time of the experimental setup is fast. For both
microgel systems, the release rate is observed to decrease as
the microgel concentration is raised. Interestingly, a release lag
time is evident for the charged microgels but not for the neutral
microgels. This suggests that the charges modulate the way in
which the naltrexone is released from the microgels. To quan-
tify the variations in the release profiles, the curves have been
fitted with the Weibull equation (Eq. 2). The solid lines in Figure
4 represent the fitted curves, and this illustrates that the data
is well represented by the Weibull equation. The good fitting
of the experimental data with the Weibull equation suggests
that practically all of the naltrexone is encapsulated within the
particles leaving an insignificant amount of unencapsulated
naltrexone in the suspension. Accordingly, naltrexone is proba-
bly attached to the microgels through associative interactions,
as drug molecules that are just dissolved in the solvent inside
the swollen microgels are expected to be pushed out of the mi-
crogels when they are heated up above the LCST.15,27
Figure 4. In vitro release profiles of naltrexone (0.02 wt %) from the
two microgels in buffered suspensions (pH 7.4) at various microgel
concentrations at 37◦C. The sample denoted “0 wt % microgel” consists
of naltrexone dissolved in PBS in the absence of microgel. The lines are
fitted with the aid of Eq. (2).
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Figure 5. The effect of microgel concentration for the two microgels
on (a) the lag time (t0), (b) the rate constant (τd), and (c) the shape
parameter (β) for samples containing 0.02 wt % of naltrexone.
Although the neutral microgels did not exhibit any release
lag time, a significant lag time was observed for the charged
microgels (see Fig. 5a). For most release studies from uncoated
micro/nanoparticles, no release lag time is observed, and a burst
release effect is much more common.48 However, a significant
lag time has been detected for some micro- and nanoparticle
systems.49 In this study, the lag times were attributed to a
combination of a very low adsorption of the probe molecules
onto the surface of the particles and migration of the probe from
the inner regions of the particles to their surface. Accordingly,
the lag times observed for the charged microgels indicate that
practically all of the naltrexone is encapsulated well within the
microgels.
The absence of a lag time for the neutral microgels suggests
that the charged groups play a vital role in inducing the lag
times. Naltrexone has pKa values of about 8.1 (proton on N) and
9.5 (phenolic proton) at 37◦C,30 and can therefore be expected to
be positively charged at the considered pH of 7.4. Considering
the relatively high salinity of the buffer, some screening of elec-
trostatic interactions in the system is expected. Unfortunately,
the microgel suspensions are too turbid for zeta potential de-
termination at the considered conditions. However, zeta poten-
tial measurements of other charged particles at corresponding
salinities show that even though the addition of salt reduces the
zeta potentials, the particles can still have a significant charge
at these conditions.50–52 It is therefore reasonable to assume
that there are attractive electrostatic interactions between the
positively charged drug and the negatively charged PAA groups
that are distributed throughout the charged microgels.
Tas¸delen et al.14 found that the addition of charged
poly(itaconic acid) groups to PNIPAAM microspheres slowed
down the drug release from the particles due to electrostatic in-
teractions with oppositely charged drugs. Although no release
lag time was observed for this system, it was found that the
charged groups prevented a significant part of the drugs to be
released from the particles due to specific binding of the drugs
to the dissociated acid groups. In our case, all naltrexone was
released from the microgels, but the electrostatic interactions
between the drug and the oppositely charged microgels causes
a lag time before any drug is released from the particles. The lag
time is increasing when the microgel concentration is raised.
The reason for this will be discussed below.
Figure 5b shows the rate constant (τ d), corresponding to the
time (after the initial lag time) it takes to release 63.2% of the
encapsulated naltrexone (see Eq. 2). It can be observed from
Figure 5b that an increase in the microgel concentration re-
sults in a slower release of the drug. As increasing the microgel
concentration can cause enhanced aggregation of the micro-
gels into larger particles,29 the slower release rates might be
due to the larger sizes (see Evaluation of the Release Rates
above). At high microgel concentrations, td is no longer depen-
dent on the amount of microgel present. This could be because
the specific leak surface becomes less size dependent for large
particles.
It is obvious from Figure 5b that the release of naltrexone is
slower for the negatively charged microgels than for the neutral
ones. Slower release rates might be caused by larger or more
compact particles, or by stronger interactions between the drug
and the microgel. However, at very low polymer concentrations,
the addition of this small amount of charges to the PNIPAAM
microgels had little effect on contraction and aggregation of the
microgel suspensions.29 Even if the charges should influence
the aggregation and contraction behavior of the microgels at
the higher microgel concentrations and higher ionic strength
utilized in this study, the charges are expected to reduce the
tendency to form large aggregates, and in addition the repul-
sive electrostatic forces should also make the microgels less
compact. It is therefore unlikely that the slower release rates
observed for the charged microgels are due to larger particles
or a more tight structure within the charged microgels. Accord-
ingly, it is reasonable to assume that the slower release rates
are caused by the attractive electrostatic interactions between
the drug and the oppositely charged microgels.
The shape parameter, β, is plotted as a function of microgel
concentration in Figure 5c. β values in the range 0.39–0.69 indi-
cate diffusion in a fractal or disordered substrate different from
a percolation cluster, values in the range 0.69–0.75 suggest dif-
fusion in normal Euclidian space, whereas values between 0.75
and 1 are indicative for diffusion in normal Euclidian space
with a contribution of another release mechanism.36 The β val-
ues for the charged microgels are all in the range between 0.75
and 1. This seems reasonable as the charges will prevent the
microgels from contracting too much; thereby leaving a net-
work that is open enough for the naltrexone to diffuse through
as a normal Euclidian space. This β range also indicates that
there is an additional release mechanism, which is in agree-
ment with the electrostatic interactions between the drug and
the oppositely charged microgels.
At low microgel concentrations, the neutral microgel has β
values around 0.69. Accordingly, the release mechanism is ei-
ther due to diffusion in a fractal or disordered substrate or
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in normal Euclidian space. At high microgel concentrations,
the β values of the neutral microgels are in the region 0.75–
1. This suggests diffusion in normal Euclidian space with a
contribution of another release mechanism, which is probably
caused by hydrophobic interactions between naltrexone and the
microgels.
For both microgel systems, the β values seem to be somewhat
higher when the microgel concentration is raised. Increasing
the microgel concentration can induce aggregation and thereby
the formation of larger particles.29 However, increased particle
size is expected to decrease the values of β.42 β is also dependent
on the intermolecular distances within the matrix, and will
increase when the intermolecular distances become larger,42
that is, when the matrix structure is more open. This might
explain why the charged microgels, which are expected to be
more swollen due to electrostatic repulsions, have higher β val-
ues than the neutral microgels at low microgel concentrations.
It is possible that an increased microgel concentration causes
enhanced associations between the polymer chains inside the
particles. These associations may lead to the formation of a
more inhomogeneous intraparticle network with a more open
structure,53,54 which might cause the observed increase in β.
Another possible explanation for the increased β values at high
microgel concentrations is that the release profile is influenced
by enhanced hydrophobic interactions between naltrexone and
the microgels.
Because the naltrexone seemed to be completely encapsu-
lated within the microgels when a naltrexone concentration
of 0.02 wt % was used, it was also interesting to examine
whether the microgels were capable of encapsulating even
higher amounts of the drug. We therefore carried out some ex-
periments where the microgel concentration was kept constant
at 1.0 wt %, and the naltrexone concentration was increased
from 0.02 to 0.08 wt %. Figure 6 shows the drug release profiles
for the two microgel suspensions at three different naltrexone
concentrations. As for the previous results, the curves were fit-
ted to the Weibull equation (Eq. 2), and the fitted curves give
a good representation of the measured data. There is a clear
change in the release profile when the naltrexone concentra-
tion is raised above 0.02 wt % for the charged microgel (Fig. 6b),
whereas the effect of naltrexone concentration is less obvious
for the neutral microgels (Fig. 6a).
Interestingly, the release lag time of the charged microgels
is independent on the naltrexone concentration (see Fig. 7a).
We have already established that the lag time is due to electro-
static interactions, and that increasing the microgel concentra-
tion causes longer lag times. As the naltrexone concentration
does not affect the lag time, the ratio between naltrexone and
the charged groups on the microgels is not the determining fac-
tor. The microgel concentration dependency (Fig. 5a) therefore
indicates that the lag time is dependent on the characteristics
of the microgel aggregates. This seems reasonable as the micro-
gels are expected to form larger aggregates when the microgel
concentration is increased. The lag time should be dependent
on the time it takes the drug to diffuse from its location inside
the particles and out to the surface. Therefore, the longer lag
times at higher microgel concentrations (Fig. 5a) are probably
due to an increased size of the microgel aggregates. At a con-
stant microgel concentration, the sizes of the aggregates do not
change much when different amounts of naltrexone are added
to the samples, and the lag time is therefore independent of the
naltrexone concentration (Fig. 7a).
Figure 6. The effect of naltrexone concentration on the in vitro re-
lease profiles of naltrexone from 1.0 wt % of the two microgels in
buffered suspensions (pH 7.4) at 37◦C. The lines are fitted with the
aid of Eq. (2).
As can be seen from Figure 7b, for the charged microgels the
release of the drug is faster when the drug loading is raised.
However, for the neutral microgels there is no significant ef-
fect of naltrexone concentration on the release rates. At the
highest naltrexone concentration, the release times for the two
microgels are quite close to each other. This suggests that the
faster release rates for the charged microgels at higher nal-
trexone concentrations might be due to a reduction of available
charged groups on the microgels per naltrexone unit.
For the neutral microgels, the shape parameter, β, is not sig-
nificantly affected by the naltrexone concentration. However,
for the charged microgels, the value of β decreases as the nal-
trexone concentration is raised (see Fig. 7c). It is possible that
more of the charged PAA groups are associated with the op-
positely charged drug at high naltrexone concentrations. Ac-
cordingly, the effective amount of repulsive forces within the
microgels decreases. Without the repulsive forces, a more com-
pact network is formed within the microgels (reminiscent of the
neutral microgels). This is in agreement with Monte Carlo sim-
ulations, which predict a decrease of β when the intermolecular
distances within the matrix decreases.42
CONCLUSIONS
Poly(N-isopropylacrylamide) microgels without attached PAA
chains and negatively charged PNIPAAM-co-PAA micro-
gels were found to show sustained release of naltrexone.
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Figure 7. The effect of naltrexone concentration for the two microgels
on (a) the lag time (t0), (b) the rate constant (τd), and (c) the shape
parameter (β) for samples containing 1.0 wt % of the two microgels.
The release curves could successfully be represented by the
Weibull equation.
Attractive associative interactions between naltrexone and
oppositely charged microgels cause slower release times com-
pared with the neutral microgels. The charges also cause the
drug to diffuse further into the microgel aggregates, resulting
in a release lag time.
Increasing the polymer concentration is expected to cause
enhanced aggregation of the microgel suspensions. The result-
ing aggregates have a smaller specific leak surface, and ac-
cordingly the drug release times become longer. The larger
aggregates also increase the release lag time of the charged
microgels.
For the neutral microgels, the drug release is not signifi-
cantly influenced by the naltrexone concentration. However,
for the charged microgels both the drug release rates and the
β values are declining when the naltrexone content becomes
higher. This might be caused by the reduced ratio between the
charged groups on the microgels and the oppositely charged
naltrexone. However, the amount of charged groups on the mi-
crogels is still high enough to prevent the release lag time from
being affected by the naltrexone concentration.
The tested concentrations of the microgels did not exhibit
any significant cytotoxic effect on a HeLa cells, making them
promising candidates for drug delivery purposes. They also
have the additional advantage of providing a system where
the drug is easily loaded into the microgels, without any time-
consuming preparation procedures or the use of hash solvent
conditions or severe mechanical stress.
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